Acrivon Therapeutics Stock Rises 14% On FDA Recognition For ACR-368 OncoSignature Assay

(RTTNews) - Acrivon Therapeutics, Inc. (ACRV) is up by 14 percent on Wednesday. The stock surged after the company announced that the U.S. Food and Drug Administration granted a special status to its ACR-368 OncoSignature assay, a multiplex immunofluorescence test designed to identify endometrial cancer patients who may benefit from ACR-368 treatment.

ACRV is currently trading at $6.77, up $0.86 from the previous close of $5.91. The stock has fluctuated today, reaching a high of $8.00 and a low of $5.83. Trading volume has soared to 0.67 million shares, significantly above the average of 0.05 million.

The stock remains within its 52-week range of $3.19 to $11.90. This recognition indicates that the FDA sees the test as having the potential to improve the treatment or diagnosis of life-threatening conditions.